- Policy
- Transferred drugs exempted from stepped pricing reduction
- by Kim, Jung-Ju Dec 23, 2020 06:10am
- The South Korean government is to enforce an amendment in the ‘stepped drug pricing system’ from next year to remove the issue regarding the drugs reapplying for listin6g due to corporate transfer. The government created a new legal basis to solve the problem raised by the pharmaceutical and bio industry that the new generic pricing sy
- Policy
- MOHW nominee to “Expand coverage on expensive new drug”
- by Lee, Jeong-Hwan Dec 23, 2020 06:09am
- The Minister of Health and Welfare nominee Kwon Deok-cheol expressed his determination to analyze the financial impact that immunotherapy and other high-priced new drugs would have on the National Health Insurance, and to expand reimbursement centering drugs with high social demand. He also answered enhancing the patients’ access to pha
- Policy
- Benefit standards of Zometa Ready & Xgeva are expanded
- by Lee, Hye-Kyung Dec 23, 2020 06:09am
- The administration conditions for Zometa Ready (Zoledronic acid) of SciGen Korea and Xgeva (Denosumab) of Amgen Korea, which are used to treat patients with multiple myeloma and solid cancer bone metastasis, will be changed. Previously, both drugs were reimbursed only when they showed lytic findings on plain X-rays, normal on X-rays, or when
- Policy
- “Just worrying about new pricing system gets you nowhere”
- by Eo, Yun-Ho Dec 22, 2020 06:12am
- A vast number of patients are suffering in vain and pain as more drugs are available without the healthcare insurance benefit. Now, the coverage on new drug is developing into an issue for the general South Korean public. Although the South Korean government tried to expand the scope of risk sharing agreement (RSA) and pharmacoeconomic e
- Policy
- MFDS initiated a preliminary review of Pfizer's vaccine
- by Lee, Tak-Sun Dec 22, 2020 06:09am
- In Korea, the approval process for Pfizer's COVID-19 vaccine has also begun. The MFDS requested a preliminary review of non-clinical and clinical (Phase I, II, and III) data before Pfizer applied for a COVID-19 vaccine license on the 18th. On the same day, AstraZeneca also announced that it applied for an additional preliminary review of
- Policy
- What is the future COVID-19 vaccination plan?
- by Lee, Tak-Sun Dec 21, 2020 06:19am
- The government's plan and schedule for introducing COVID-19 vaccine have been established. It was introduced within the first quarter through a pre-purchase with AstraZeneca, and the contract with Pfizer, Modena, and Janssen, which contracts were delayed, will undergo import procedures after the second quarter. Therefore, early approval of
- Policy
- MOHW to reduce pricing in combination drug changing API
- by Kim, Jung-Ju Dec 21, 2020 06:19am
- The South Korean government is to reevaluate and reduce the reimbursed pricing on drugs that changed the main active pharmaceutical ingredient (API) due to the change of labeling. Immediately, calcium chloride combination injections are subjected to the new change with the updated list of reimbursed drug effective from Dec. 1. As it woul
- Policy
- Low dose in multiple Vizimpro reduces the insurance benefit
- by Lee, Hye-Kyung Dec 21, 2020 06:18am
- If Pfizer Korea's Vizimpro is prescribed at a low dose in multiple, the benefit will be reduced. The price difference between 1 tablet of Vizimpro 45mg (&8361;32,105/tab) and 3 tablets of Vizimpro 15mg (&8361;16,052/tab) is &8361;16,051, and the difference between 1 tabelt of Vizimpro 30mg and 2 tablets of Vizimpro 15mg is &8361;6,420
- Policy
- Lee Nak-yon “Nationwide fast COVID-19 testing for all"
- by Lee, Jeong-Hwan Dec 18, 2020 06:05am
- The Democratic Party is to consult with the government and relevant experts to review the necessity of testing everyone in South Korea for COVID-19 via the fast antigen testing kits. At a National Assembly meeting for the political party leaders convened on Dec. 14, the ruling party leader Lee Nak-yon said, “It is time to discuss having
- Policy
- “Despite vaccine delay, Phase III to complete in 2021"
- by Kim, Jung-Ju Dec 17, 2020 06:11am
- While Genexine’s South Korean-made COVID-19 vaccine trial is expected to get delayed due to change in candidate substance, the health authority reiterated their goal to complete a Phase III clinical trial for a Korean-made vaccine in the latter half of next year is unchanged. Also the official added the global vaccine supply for 1.2 bi
